» Articles » PMID: 37435495

Treatment of Obesity-related Diabetes: Significance of Thermogenic Adipose Tissue and Targetable Receptors

Overview
Journal Front Pharmacol
Date 2023 Jul 12
PMID 37435495
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes mellitus is mainly classified into four types according to its pathogenesis, of which type 2 diabetes mellitus (T2DM) has the highest incidence rate and is most relevant to obesity. It is characterized by high blood glucose, which is primarily due to insulin resistance in tissues that are responsible for glucose homeostasis (such as the liver, skeletal muscle, and white adipose tissue (WAT)) combined with insufficiency of insulin secretion from pancreatic β-cells. Treatment of diabetes, especially treatment of diabetic complications (such as diabetic nephropathy), remains problematic. Obesity is one of the main causes of insulin resistance, which, however, could potentially be treated by activating thermogenic adipose tissues, like brown and beige adipose tissues, because they convert energy into heat through non-shivering thermogenesis and contribute to metabolic homeostasis. In this review, we summarize the function of certain anti-diabetic medications with known thermogenic mechanisms and focus on various receptor signaling pathways, such as previously well-known and recently discovered ones that are involved in adipose tissue-mediated thermogenesis and could be potentially targeted to combat obesity and its associated diabetes, for a better understanding of the molecular mechanisms of non-shivering thermogenesis and the development of novel therapeutic interventions for obesity-related diabetes and potentially diabetic complications.

Citing Articles

Brown and Beige Adipose Tissue: One or Different Targets for Treatment of Obesity and Obesity-Related Metabolic Disorders?.

Kononova Y, Tuchina T, Babenko A Int J Mol Sci. 2025; 25(24.

PMID: 39769065 PMC: 11677471. DOI: 10.3390/ijms252413295.


Triglyceride to high-density lipoprotein cholesterol ratio is associated with diabetes incidence in non-obese individuals with normoglycemia: a retrospective cohort study based on individuals from East Asia.

Huang Z, Zhang X, Sun D, Yu K Front Endocrinol (Lausanne). 2024; 15:1442731.

PMID: 39588337 PMC: 11586199. DOI: 10.3389/fendo.2024.1442731.


Targeting the Adipose Tissue-Liver-Gut Microbiota Crosstalk to Cure MASLD.

Gabbia D, De Martin S Biology (Basel). 2023; 12(12).

PMID: 38132297 PMC: 10741127. DOI: 10.3390/biology12121471.


Drugs for Diabetes: From Pharmacology to Clinical Application.

Srivastava S Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895817 PMC: 10610375. DOI: 10.3390/ph16101346.

References
1.
Ozeki Y, Masaki T, Kamata A, Miyamoto S, Yoshida Y, Okamoto M . The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study. Medicines (Basel). 2022; 9(9). PMC: 9502467. DOI: 10.3390/medicines9090047. View

2.
McLean B, Wong C, Kaur K, Seeley R, Drucker D . Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide. JCI Insight. 2021; 6(22). PMC: 8663785. DOI: 10.1172/jci.insight.153732. View

3.
Florez H, Luo J, Castillo-Florez S, Mitsi G, Hanna J, Tamariz L . Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med. 2010; 122(2):112-20. DOI: 10.3810/pgm.2010.03.2128. View

4.
Armani A, Cinti F, Marzolla V, Morgan J, Cranston G, Antelmi A . Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB J. 2014; 28(8):3745-57. DOI: 10.1096/fj.13-245415. View

5.
Jespersen N, Feizi A, Andersen E, Heywood S, Hattel H, Daugaard S . Heterogeneity in the perirenal region of humans suggests presence of dormant brown adipose tissue that contains brown fat precursor cells. Mol Metab. 2019; 24:30-43. PMC: 6531810. DOI: 10.1016/j.molmet.2019.03.005. View